(Q29615385)

title

Cisplatin: mode of cytotoxic action and molecular basis of resistance (English)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14576837

30 April 2017

0 references

1 reference

antineoplastic resistance

1 reference

14576837

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14576837

24 March 2024

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

24 March 2024

author name string

Zahid H. Siddik

1

1 reference

14576837

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14576837

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14576837

24 March 2024

language of work or name

1 reference

30 April 2017

publication date

20 October 2003

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14576837

full work available at URL

30 April 2017

https://www.nature.com/articles/1206933.pdf

1 reference

14576837

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14576837

https://www.nature.com/articles/1206933.pdf

24 March 2024

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

https://www.nature.com/articles/1206933

24 March 2024

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

24 March 2024

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14576837

30 April 2017

volume

22

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14576837

30 April 2017

issue

47

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14576837

30 April 2017

page(s)

7265-79

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14576837

p53-Mdm2--the affair that never ends

30 April 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

The neu oncogene encodes an epidermal growth factor receptor-related protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

A family of drug transporters: the multidrug resistance-associated proteins.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Rescuing the function of mutant p53.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Regulation of cell death protease caspase-9 by phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

DNA repair: enzymatic mechanisms and relevance to drug response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Specificity of platinum–DNA adduct repair

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Cisplatinum and taxol induce different patterns of p53 phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Cisplatin resistance and oncogenes--a review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Recombinant adenovirus-mediated p14(ARF) overexpression sensitizes human breast cancer cells to cisplatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Glutathione-mediated activation of anticancer platinum(IV) complexes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

New members of the Bcl-2 family and their protein partners

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

MEKK1/JNK signaling stabilizes and activates p53.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Identification of p53 genetic suppressor elements which confer resistance to cisplatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Cellular accumulation of the anticancer agent cisplatin: a review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Clinical perspectives on platinum resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Cisplatin/carboplatin cross-resistance in ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

BRCA1 required for transcription-coupled repair of oxidative DNA damage

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Cell cycle control and cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Bcl-2 functions in an antioxidant pathway to prevent apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

p53 mutations in human cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Preclinical perspectives on platinum resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Synthesis and in Vitro and in Vivo Antitumor Activity of a Series of Trans Platinum Antitumor Complexes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Meeting report on 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Overexpression of metallothionein confers resistance to anticancer drugs.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Regulation of p53 in response to DNA damage

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Diverse functions of JNK signaling and c-Jun in stress response and apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Mechanisms of switching on p53: a role for covalent modification?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

p53 and ATM: cell cycle, cell death, and cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Metallothionein levels in ovarian tumours before and after chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Regulation of p53: intricate loops and delicate balances

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Sequence-specific transcriptional activation is essential for growth suppression by p53.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Mitogen-activated protein kinase pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Mechanisms of DNA excision repair

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Regulation of p73 by c-Abl through the p38 MAP kinase pathway.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Specific in vitro binding of p53 to the promoter region of the human mismatch repair gene hMSH2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Anticancer drug targets: cell cycle and checkpoint control.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Premature p34cdc2 activation required for apoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

The p53-Regulated Cyclin G Gene Promotes Cell Growth: p53 Downstream Effectors Cyclin G and Gadd45 Exert Different Effects on Cisplatin Chemosensitivity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Requirement for ERK activation in cisplatin-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Requirement of ATM in UVA-induced signaling and apoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206933

7 January 2021

Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells.

4

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Post-translational modifications and activation of p53 by genotoxic stresses

24 March 2024

7

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Enhanced resistance of HeLa cells to cisplatin by overexpression of gamma-glutamyltransferase

24 March 2024

31

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines

24 March 2024

33

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Genomic dissection reveals locus response to stress for mammalian acetylcholinesterase.

24 March 2024

37

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

The antitumour activity of alkylating agents is not correlated with the levels of glutathione, glutathione transferase and O6-alkylguanine-DNA-alkyltransferase of human tumour xenografts

24 March 2024

38

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Reactions of cisplatin hydrolytes with methionine, cysteine, and plasma ultrafiltrate studied by a combination of HPLC and NMR techniques

24 March 2024

49

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate-use experience

24 March 2024

50

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Modulation of cytotoxicity of chemotherapeutic drugs by activated H-ras

24 March 2024

51

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.

24 March 2024

57

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

How nucleotide excision repair protects against cancer

24 March 2024

61

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells

24 March 2024

72

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

ras mutation and platinum resistance in human ovarian carcinomas in vitro

24 March 2024

91

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.

24 March 2024

98

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

High mobility group protein-1 (HMG-1) is a unique activator of p53

24 March 2024

99

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

The role of DNA repair in resistance of L1210 cells to isomeric 1,2-diaminocyclohexaneplatinum complexes and ultraviolet irradiation

24 March 2024

101

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Molecular mechanisms involved in cisplatin cytotoxicity.

24 March 2024

103

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Mechanisms of resistance to cisplatin

24 March 2024

104

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

New platinum antitumor complexes

24 March 2024

108

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Activation of MEK kinase 1 by the c-Abl protein tyrosine kinase in response to DNA damage

24 March 2024

116

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours

24 March 2024

117

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system

24 March 2024

119

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Enhanced DNA repair and resistance to cisplatin in human ovarian cancer

24 March 2024

123

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage

24 March 2024

125

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

p53 interacts with the DNA mismatch repair system to modulate the cytotoxicity and mutagenicity of hydrogen peroxide

24 March 2024

129

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Damage-induced Bax N-terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate

24 March 2024

130

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis

24 March 2024

132

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer

24 March 2024

134

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network

24 March 2024

136

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin

24 March 2024

138

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs

24 March 2024

145

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP.

24 March 2024

148

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Loss of p73 induction in a cisplatin-resistant bladder cancer cell line

24 March 2024

152

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines

24 March 2024

154

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Ovarian cancer: new clinical approaches

24 March 2024

155

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Chemotherapy for advanced epithelial ovarian cancer

24 March 2024

156

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

High-Dose Cisplatin in Hypertonic Saline

24 March 2024

157

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype

24 March 2024

159

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA.

24 March 2024

164

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Cisplatin (cis-diamminedichloroplatinum II)

24 March 2024

165

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells.

24 March 2024

166

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.

24 March 2024

167

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Metallothionein gene expression and resistance to cisplatin in human ovarian cancer

24 March 2024

180

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

New therapies for ovarian cancer

24 March 2024

181

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Mechanisms of p53-dependent apoptosis

24 March 2024

183

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Alteration in p53 pathway and defect in apoptosis contribute independently to cisplatin-resistance

24 March 2024

184

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

p16INK4A Participates in a G1 Arrest Checkpoint in Response to DNA Damage

24 March 2024

186

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Nitrone spin traps and a nitroxide antioxidant inhibit a common pathway of thymocyte apoptosis

24 March 2024

197

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

The p53 tumor suppressor gene: from molecular biology to clinical investigation.

24 March 2024

202

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Mechanisms of transcription-coupled DNA repair

24 March 2024

204

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II)

24 March 2024

206

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines.

24 March 2024

214

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient.

24 March 2024

215

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation

24 March 2024

217

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1

24 March 2024

223

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells

24 March 2024

225

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206933

24 March 2024

Identifiers

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14576837

30 April 2017

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

1035533524

0 references

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14576837

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017